MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

NCT01273181 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

NIH

Sponsor class

Conditions

Metastatic Cancer
Metastatic Renal Cancer
Metastatic Melanoma

Interventions

BIOLOGICAL: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes
DRUG: Aldesleukin
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)